Research programme: infectious disease vaccines - VaxInnate
Alternative Names: flagellin.AvHA; flagellin.AvM2e; Hemagglutinin (HA)-based pandemic influenza vaccines - VaxInnate; Hemagglutinin (HA)-based seasonal influenza vaccines - VaxInnate; Human papillomavirus (HPV) vaccine - VaxInnate; Respiratory syncytial virus (RSV) infections - VaxInnate; Swine flu vaccine - VaxInnateLatest Information Update: 14 Sep 2023
At a glance
- Originator VaxInnate
- Class Bacterial vaccines; Influenza A vaccines; Papillomavirus vaccines; Recombinant fusion proteins; Viral vaccines
- Mechanism of Action Immunostimulants; Toll-like receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Clostridium difficile infections; Human papillomavirus infections; Influenza A virus H1N1 subtype; Influenza A virus H5N1 subtype; Respiratory syncytial virus infections
Most Recent Events
- 08 Oct 2015 Preclinical trials in Clostridium difficile infections in USA (Parenteral)
- 24 Feb 2011 VaxInnate receives a contract from the Biomedical Advanced Research and Development Authority (BARDA) for development of Recombinant influenza vaccines in USA
- 13 Jan 2010 Swine flu vaccine licensed to Biological E in India